MD Anderson and Ochsner Health announce partnership to create first fully integrated cancer program in Louisiana
The University of Texas MD Anderson Cancer Center and New Orleans-based Ochsner Health today announced a partnership to create Ochsner MD Anderson Cancer Center in southeastern Louisiana. Cancer patients in the region now have access to cancer treatments that are among the most advanced in the nation. Through this collaboration, Ochsner is the first and only provider in Louisiana with a fully integrated cancer program based...
MD Anderson and Replay announce FDA clearance of IND application for first-in-class TCR NK cell therapy for sarcoma
The University of Texas MD Anderson Cancer Center and Replay today announced that the Food & Drug Administration (FDA) has issued...
ASCO: Targeted therapy achieves responses across multiple cancer types with FGFR alterations
ABSTRACTS: 3121, 4504, LBA4619
Three clinical trials led by researchers at The University of Texas MD Anderson Cancer Center demonstrated...
ASCO: Targeted therapy induces responses in HER2-amplified biliary tract cancer
ABSTRACT: 4008
HER2-targeted bispecific antibody zanidatamab demonstrated durable responses in patients with treatment-refractory HER2-positive biliary tract cancer (BTC), researchers from The University of Texas MD Anderson Cancer Center reported at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. The study results also were published today in The Lancet Oncology.
In the first cohort of the global Phase...
